| scholarly article | Q13442814 |
| P50 | author | Tomas Garzon-Muvdi | Q86453684 |
| P2093 | author name string | Michael Lim | |
| Andrew S Luksik | |||
| Russell Maxwell | |||
| P2860 | cites work | Cancer genome landscapes | Q22242276 |
| CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms | Q24534904 | ||
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 | Q24634871 | ||
| Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells | Q24645109 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation | Q24676080 | ||
| Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction | Q26749333 | ||
| Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities | Q26775383 | ||
| Antagonists of PD-1 and PD-L1 in Cancer Treatment | Q26796311 | ||
| Molecular and cellular insights into T cell exhaustion | Q26800047 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. | Q27853339 | ||
| Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. | Q27853362 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies | Q28072007 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor | Q28144319 | ||
| Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice | Q28201627 | ||
| PD-L2 is a second ligand for PD-1 and inhibits T cell activation | Q28202471 | ||
| CTLA-4 can function as a negative regulator of T cell activation | Q28235866 | ||
| Activation-induced expression of human programmed death-1 gene in T-lymphocytes | Q28237441 | ||
| CD28 and CTLA-4 coreceptor expression and signal transduction | Q28244243 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Enhancement of antitumor immunity by CTLA-4 blockade | Q28275730 | ||
| Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes | Q28282689 | ||
| Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Q48594003 | ||
| Epidemiology of brain metastases | Q48829653 | ||
| Irradiation induces increase of adhesion molecules and accumulation of beta2-integrin-expressing cells in humans | Q52767276 | ||
| A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy | Q52863948 | ||
| The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression | Q53075820 | ||
| Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats | Q53774802 | ||
| Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. | Q55467906 | ||
| Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. | Q55475091 | ||
| Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity | Q56902023 | ||
| Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer | Q56903097 | ||
| Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors | Q56909582 | ||
| Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium | Q71767581 | ||
| Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells | Q73331004 | ||
| Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy | Q73496463 | ||
| IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells | Q81017812 | ||
| Gamma-ray resistance of regulatory CD4+CD25+Foxp3+ T cells in mice | Q82620895 | ||
| Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 | Q28284177 | ||
| A new member of the immunoglobulin superfamily--CTLA-4 | Q28299244 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors | Q29619686 | ||
| Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy | Q29619961 | ||
| Immunologic correlates of the abscopal effect in a patient with melanoma | Q29620334 | ||
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 | ||
| Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 | ||
| Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma | Q29620812 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| PD-L1 regulates the development, maintenance, and function of induced regulatory T cells | Q30080038 | ||
| CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. | Q30373363 | ||
| Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. | Q30515733 | ||
| Medical management of brain tumor patients | Q31134402 | ||
| Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications | Q33358579 | ||
| Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model | Q33374014 | ||
| Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model | Q33613430 | ||
| Minireview: Glucocorticoids in Autoimmunity: Unexpected Targets and Mechanisms | Q33636927 | ||
| Immunogenic and tolerogenic cell death | Q33639097 | ||
| The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity | Q33670728 | ||
| Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline | Q33763941 | ||
| Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas | Q33778706 | ||
| Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation | Q33802647 | ||
| Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment | Q33865925 | ||
| Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model | Q33889603 | ||
| PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine | Q33950150 | ||
| Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation | Q34052833 | ||
| γ-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo | Q34091374 | ||
| Long-term survival with metastatic cancer to the brain | Q34103604 | ||
| VEGF in brain tumors | Q34178821 | ||
| Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. | Q34276759 | ||
| SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation | Q34331884 | ||
| PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta | Q34347206 | ||
| Inhibitory B7-family molecules in the tumour microenvironment | Q37171804 | ||
| Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade | Q37173548 | ||
| Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma | Q37222679 | ||
| MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. | Q37331928 | ||
| Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody | Q37351567 | ||
| Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection | Q37397827 | ||
| Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. | Q37524200 | ||
| The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline | Q37643538 | ||
| Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models | Q37647868 | ||
| Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas | Q37658308 | ||
| The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy. | Q37708839 | ||
| Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab | Q38012057 | ||
| Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade | Q38377528 | ||
| Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma | Q38393470 | ||
| Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group | Q38573324 | ||
| Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy | Q38732479 | ||
| Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy | Q38743794 | ||
| Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas | Q38760734 | ||
| PD-1 Restrains Radiotherapy-Induced Abscopal Effect. | Q38907646 | ||
| Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4+ FoxP3+ regulatory T cells | Q39292669 | ||
| Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells | Q39370246 | ||
| HMGB1 is an endogenous immune adjuvant released by necrotic cells | Q40104101 | ||
| Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. | Q40151555 | ||
| B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. | Q40405936 | ||
| Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes | Q40497215 | ||
| Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis | Q40617310 | ||
| Brain metastases. Histology, multiplicity, surgery, and survival | Q40923255 | ||
| Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation | Q40957673 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| Dexamethasone enhances CTLA-4 expression during T cell activation | Q41696986 | ||
| An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. | Q41790713 | ||
| Consensus guidelines for the detection of immunogenic cell death | Q42553556 | ||
| PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A | Q42940055 | ||
| The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma | Q43133266 | ||
| Lymphoproliferation in CTLA-4–Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4 + T Cells | Q46091258 | ||
| Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma | Q46110144 | ||
| Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model | Q46120052 | ||
| Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma | Q46586294 | ||
| Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function | Q48220006 | ||
| CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo | Q48266405 | ||
| Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model | Q48287471 | ||
| Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors | Q48425406 | ||
| A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy | Q48582050 | ||
| Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. | Q34509694 | ||
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Q34522172 | ||
| Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis | Q34535189 | ||
| Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion. | Q34775318 | ||
| Radiation Enhances Regulatory T Cell Representation | Q35053414 | ||
| Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide | Q35167257 | ||
| Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans | Q35220386 | ||
| Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer | Q35463514 | ||
| Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy | Q35540109 | ||
| The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells | Q35743681 | ||
| Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment | Q35787908 | ||
| Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma | Q35815273 | ||
| Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies | Q35841880 | ||
| Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab | Q35895159 | ||
| Molecular mechanisms of brain tumor edema | Q35961516 | ||
| Sequential Immunotherapy by Vaccination With GM-CSF–expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors | Q35962460 | ||
| Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis | Q36082471 | ||
| Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. | Q36142366 | ||
| CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. | Q36284594 | ||
| Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer | Q36301801 | ||
| CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells | Q36366857 | ||
| Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp | Q36375152 | ||
| Mechanisms of immune evasion by tumors | Q36490750 | ||
| PD-L1 expression and prognostic impact in glioblastoma | Q36493843 | ||
| Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial | Q36726204 | ||
| Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion | Q36883024 | ||
| Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. | Q36907372 | ||
| Bevacizumab for the treatment of glioblastoma. | Q36929502 | ||
| Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients | Q36972613 | ||
| Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages | Q37092938 | ||
| P577 | publication date | 2017-03-03 | |
| P1433 | published in | Neurotherapeutics | Q15716631 |
| P1476 | title | The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors |
| Q90067528 | CT-2A neurospheres-derived high-grade glioma in mice: a new model to address tumor stem cells and immunosuppression |
| Q50109459 | Current state and future prospects of immunotherapy for glioma |
| Q91565673 | Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma |
| Q61809953 | Immune checkpoint inhibitors: Advances and impact in neuro-oncology |
| Q60049874 | Specific clinical and immune features of CD68 in glioma via 1,024 samples |
Search more.